Sensory gating, Cannabinoids and Schizophrenia

Neuropharmacology

Volumn 67, Issue , 2013, Pages 66-77

  Dissanayake, Dilshani W N ^a   Mason, Robert ^b   Marsden, Charles A ^b  

^a UNIVERSITY OF COLOMBO   (Sri Lanka)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Auditory conditioning test paradigm; Cannabinoids; Cannabis; Schizophrenia; Sensory gating

Indexed keywords

CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CLOZAPINE; PLACEBO; RIMONABANT;

AGE; ATTENTION; AUDITORY STIMULATION; CAUSAL ATTRIBUTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EVOKED AUDITORY RESPONSE; HUMAN; NEUROBIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SENSORY GATING; SEX DIFFERENCE; SINGLE DRUG DOSE;

ACOUSTIC STIMULATION; ANIMALS; CANNABINOIDS; EVOKED POTENTIALS, AUDITORY; HUMANS; SCHIZOPHRENIA; SENSORY GATING;

EID: 84873330323     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.10.011     Document Type: Review

References (177)

1. L.E. Adler, E. Pachtman, R.D. Franks, M. Pecevich, M.C. Waldo, and R. Freedman Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia Biol. Psychiatry 17 1982 639 654
2. L.E. Adler, G. Rose, and R. Freedman Neurophysiological studies of sensory gating in rats: effects of amphetamine, phencyclidine, and haloperidol Biol. Psychiatry 21 1986 787 798
3. L.E. Adler, M.C. Waldo, A. Tatcher, E. Cawthra, N. Baker, and R. Freedman Lack of relationship of auditory gating defects to negative symptoms in schizophrenia Schizophr. Res. 3 1990 131 138
4. L.E. Adler, L.D. Hoffer, A. Wiser, and R. Freedman Normalization of auditory physiology by cigarette smoking in schizophrenic patients Am. J. Psychiatry 150 1993 1856 1861
5. L.E. Adler, L. Hoffer, H.T. Nagamoto, M.C. Waldo, M.A. Kisley, and J.M. Giffith Yohimbine impairs P50 auditory sensory gating in normal subjects Neuropsychopharmacology 10 1994 249 257
6. L.E. Adler, A. Olincy, M. Waldo, J.G. Harris, J. Griffith, K. Stevens, K. Flach, H. Nagamoto, P. Bickford, S. Leonard, and R. Freedman Schizophrenia, sensory gating, and nicotinic receptors Schizophr. Bull. 24 1998 189 202
7. L.E. Adler, A. Olincy, E.M. Cawthra, K.A. McRae, J.G. Harris, H.T. Nagamoto, M.C. Waldo, M.H. Hall, A. Bowles, L. Woodward, R.G. Ross, and R. Freedman Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients Am. J. Psychiatry 161 2004 1822 1828
8. L.E. Adler, E.M. Cawthra, K.A. Donovan, J.G. Harris, H.T. Nagamoto, A. Olincy, and M.C. Waldo Improved p50 auditory gating with ondansetron in medicated schizophrenia patients Am. J. Psychiatry 162 2005 386 388
9. A.P. Anokhin, A.B. Vedeniapin, A.C. Heath, O. Korzyukov, and N.N. Boutros Genetic and environmental influences on sensory gating of mid-latency auditory evoked responses: a twin study Schizophr. Res. 89 2007 312 319 Epub 2006 Oct 2
10. K.K. Anstrom, H.C. Cromwell, and D.J. Woodward Effects of restraint and haloperidol on sensory gating in the midbrain of awake rats Neuroscience 146 2007 515 524
11. P.A. Arguello, and J.D. Jentsch Cannabinoid CB1 receptor-mediated impairment of visuospatial attention in the rat Psychopharmacology (Berl) 177 2004 141 150
12. N. Baker, L.E. Adler, R.D. Franks, M. Waldo, S. Berry, H. Nagamoto, A. Muckle, and R. Freedman Neurophysiological assessment of sensory gating in psychiatric inpatients: comparison between schizophrenia and other diagnoses Biol. Psychiatry 22 1987 603 617
13. G. Bersani, V. Orlandi, G.D. Kotzalidis, and P. Pancheri Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes Eur. Arch. Psychiatry Clin. Neurosci. 252 2002 86 92
14. A.R. Best, J.V. Thompson, M.L. Fletcher, and D.A. Wilson Cortical metabotropic glutamate receptors contribute to habituation of a simple odor-evoked behaviour J. Neurosci. 25 2005 2513 2517
15. P.C. Bickford-Wimer, H. Nagamoto, R. Johnson, L.E. Adler, M. Egan, G.M. Rose, and R. Freedman Auditory sensory gating in hippocampal neurons: a model system in the rat Biol. Psychiatry 27 1990 183 192
16. P.C. Bickford, V. Luntz-Leybman, and R. Freedman Auditory sensory gating in the rat hippocampus: modulation by brainstem activity Brain Res. 607 1993 33 38
17. T. Bisogno, A. Ligresti, and V. Di Marzo The endocannabinoid signalling system: biochemical aspects Pharmacol. Biochem. Behav. 81 2005 224 238 Review
18. M. Bles, A. Alink, and B.M. Jansma Neural aspects of cohort-size reduction during visual gating Brain Res. 1150 2007 143 154
19. N.N. Boutros, J. Overall, and G. Zouridakis Test-retest reliability of the P50 mid-latency auditory evoked response Psychiatry Res. 39 1991 181 192
20. N.N. Boutros, K.A. Bonnet, R. Millana, and J. Liu A parametric study of the N40 auditory evoked response in rats Biol. Psychiatry 42 1997 1051 1059
21. N.N. Boutros, and S.W. Kwan Test-retest reliability of the rat N40 auditory evoked response: preliminary data Psychiatry Res. 81 1998 269 276
22. N.N. Boutros, A. Belger, D. Campbell, C. D'Souza, and J. Krystal Comparison of four components of sensory gating in schizophrenia and normal subjects: a preliminary report Psychiatry Res. 88 1999 119 130
23. N.N. Boutros, and A. Belger Midlatency evoked potentials attenuation and augmentation reflect different aspects of sensory gating Biol. Psychiatry 45 1999 917 922
24. N.N. Boutros, O. Korzyukov, B. Jansen, A. Feingold, and M. Bell Sensory gating deficits during the mid-latency phase of information processing in medicated schizophrenia patients Psychiatry Res. 126 2004 203 215
25. M.J. Brinkman, and J.E. Stauder Development and gender in the P50 paradigm Clin. Neurophysiol. 118 2007 1517 1524
26. A. Brockhaus-Dumke, F. Schultze-Lutter, R. Mueller, I. Tendolkar, A. Bechdolf, R. Pukrop, J. Klosterkoetter, and S. Ruhrmann Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients Biol. Psychiatry 64 2008 376 384
27. J. Brodkin, and J.M. Moerschbaecher SR141716A antagonizes the disruptive effects of cannabinoid ligands on learning in rats J. Pharmacol. Exp. Ther. 282 1997 1526 1532
28. T.H. Bullock Signals and signs in the nervous system: the dynamic anatomy of electrical activity is probably information-rich Proc. Natl. Acad. Sci. U.S.A. 94 1997 1 6
29. K.S. Cadenhead, G.A. Light, M.A. Geyer, and D.L. Braff Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder Am. J. Psychiatry 157 2000 55 59
30. K.S. Cadenhead, G.A. Light, K.M. Shafer, and D.L. Braff P50 suppression in individuals at risk for schizophrenia: the convergence of clinical, familial, and vulnerability marker risk assessment Biol. Psychiatry 57 2005 1504 1509
31. I. Cancelli, I.P. Cadore, G. Merlino, L. Valentinis, U. Moratti, P. Bergonzi, G.L. Gigli, and M. Valente Sensory gating deficit assessed by P50/Pb middle latency event related potential in Alzheimer's disease J. Clin. Neurophysiol. 23 2006 421 425
32. B.A. Clementz, M.A. Geyer, and D.L. Braff Poor P50 suppression among schizophrenia patients and their first-degree biological relatives Am. J. Psychiatry 155 1998 1691 1694
33. H.C. Cromwell, K. Anstrom, A. Azarov, and D.J. Woodward Auditory inhibitory gating in the amygdala: single-unit analysis in the behaving rat Brain Res. 1043 2005 12 23
34. H.C. Cromwell, A. Klein, and R.P. Mears Single unit and population responses during inhibitory gating of striatal activity in freely moving rats Neuroscience 25 2007 69 85
35. W.F. Costain The effects of cannabis abuse on the symptoms of schizophrenia: patient perspectives Int. J. Ment. Health Nurs. 17 2008 227 235
36. D.R. Compton, M.D. Aceto, J. Lowe, and B.R. Martin In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta-9 tetrahydrocannabinol induced responses and apparent agonist activity J. Pharmacol. Exp. Ther. 277 1996 586 594
37. B. Dean, S. Sundram, R. Bradbury, E. Scarr, and D. Copolov Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use Neuroscience 103 2001 9 15
38. N.M. de Bruin, B.A. Ellenbroek, W.J. van Schaijk, A.R. Cools, A.M. Coenen, and E.L. van Luijtelaar Sensory gating of auditory evoked potentials in rats: effects of repetitive stimulation and the interstimulus interval Biol. Psychol. 55 2001 195 213
39. N.M.W.J. de Bruin, E.L.J.M. van Luijtelaar, A.R. Cools, and B.A. Ellenbroek Filtering disturbances in schizophrenic patients. Gating of auditory evoked potentials and prepulse inhibition of the acoustic startle response compared. Emphasis on the role of dopamine Curr. Neuropharmacol. 1 2003 47 87
40. J. Desfossés, E. Stip, L.A. Bentaleb, and S. Potvin Endocannabinoids and schizophrenia Pharmaceuticals 3 2010 3101 3126 10.3390/ph3103101 Review
41. D.,C. D'Souza, E. Perry, L. MacDougall, Y. Ammerman, T. Cooper, Y.T. Wu, G. Braley, R. Gueorguieva, and J.H. Krystal The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis Neuropsychopharmacology 29 8 2004 1558 1572
42. V. De Luca, A.H. Wong, D.J. Muller, G.W. Wong, R.F. Tyndale, and J.L. Kennedy Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients Neuropsychopharmacology 29 2004 1522 1526
43. O.M. de Wilde, L.J. Bour, P.M. Dingemans, J.H. Koelman, and D.H. Linszen A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups Schizophr. Res. 97 2007 137 151
44. W.N.D. Dissanayake, M. Zachariou, C.A. Marsden, and R. Mason Auditory gating in rat hippocampus and medial prefrontal cortex: effect of the cannabinoid agonist WIN55,212-2 Neuropharmacology 55 2008 1397 1404
45. Dissanayake, W.D.N., 2008. Sensory gating in the hippocampus and the medial prefrontal cortex. PhD thesis.; University of Nottinghm, UK.
46. W.D.N. Dissanayake, M. Zachariou, C.A. Marsden, and R. Mason Effects of phencyclidine on auditory gating in the rat hippocampus and the medial prefrontal cortex Brain Res. 1298 2009 153 160
47. V. Di Marzo A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists Trends Pharmacol. Sci. 27 2006 134 140 Review
48. N. De Marchi, L. De Petrocellis, P. Orlando, F. Daniele, F. Fezza, and V. Di Marzo Endocannabinoid signalling in the blood of patients with schizophrenia Lipids Health Dis. 19 2003 2 5
49. E. Drews, M. Schneider, and M. Koch Effects of the cannabinoid receptor agonist WIN55, 212-2 on operant behavior and locomotor activity in rats Pharmacol. Biochem. Behav. 80 2005 145 150
50. C.R. Edwards, P.D. Skosnik, A.B. Steinmetz, B.F. O'Donnell, and W.P. Hetrick Auditory gating impairments in heavy cannabis users are associated with altered neural oscillations Behav. Neurosci. 123 5 2009 1065
51. H.M. Emrich, F.M. Leweke, and U. Schneider Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system-a systems-theoretical approach to psychosis Pharmacol. Biochem. Behav. 56 1997 803 807
52. M.N. Ermutlu, S. Karamursel, E.H. Ugur, L. Senturk, and N. Gokhan Effects of cold stress on early and late stimulus gating Psychiatry Res. 136 2005 201 209
53. European Medicines Agency (EMEA), 2008. The European Medicines Agency Recommends Suspension of the Marketing Authorisation of Acomplia; Press release; ref, EMEA/CHMP/537777/2008.
54. E. Fernandez-Espejo, M.P. Viveros, L. Núñez, B.A. Ellenbroek, and F. Rodriguez de Fonseca Role of cannabis and endocannabinoids in the genesis of schizophrenia Psychopharmacology 206 4 2009 531 549
55. K.A. Flach, L.E. Adler, G.A. Gerhardt, C. Miller, P. Bickford, and R.J. MacGregor Sensory gating in a computer model of the CA3 neural network of the hippocampus Biol. Psychiatry 40 1996 1230 1245
56. R.D. Franks, L.E. Adler, M.C. Waldo, J. Alpert, and R. Freedman Neurophysiological studies of sensory gating in mania: comparison with schizophrenia Biol. Psychiatry 18 1983 989 1005
57. R. Freedman, L.E. Adler, M.C. Waldo, E. Pachtman, and R.D. Franks Neurophysiological evidence for a defect in the inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients Biol. Psychiatry 18 1983 537 551
58. R. Freedman, M. Waldo, P. Bickford-Wimer, and H. Nagamoto Elementary neuronal dysfunctions in schizophrenia Schizophr. Res. 4 1991 233 243
59. R. Freedman, A. Olincy, R.G. Ross, M.C. Waldo, K.E. Stevens, L.E. Adler, and S. Leonard The genetics of sensory gating deficits in schizophrenia Curr. Psychiatry Rep. 5 2003 155 156
60. D.R. Fuerst, J. Gallinat, and N.N. Boutros Range of sensory gating values and test-retest reliability in normal subjects Psychophysiology 44 2007 620 626
61. E.L. Gardner, and S.R. Vorel Cannabinoid transmission and reward-related events Neurobiol. Dis. 5 1998 502 533
62. E.S. Ghisolfi, A.S. Prokopiuk, J. Becker, J.A. Ehlers, P. Belmonte-de-Abreu, D.O. Souza, and D.R. Lara The adenosine antagonist theophylline impairs p50 auditory sensory gating in normal subjects Neuropsychopharmacology 27 2002 629 637
63. E.S. Ghisolfi, R. Margis, J. Becker, A.P. Zanardo, I.M. Strimitzer, and D.R. Lara Impaired P50 sensory gating in post-traumatic stress disorder secondary to urban violence Int. J. Psychophysiol. 51 2004 209 214
64. E.S. Ghisolfi, E. Heldt, A.P. Zanardo, I.M. Strimitzer Jr., A.S. Prokopiuk, J. Becker, A.V. Cordioli, G.G. Manfro, and D.R. Lara P50 sensory gating in panic disorder J. Psychiatr. Res. 40 2006 535 540
65. A. Giuffrida, F.M. Leweke, C.W. Gerth, D. Schreiber, D. Koethe, J. Faulhaber, J. Klosterkötter, and D. Piomelli Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms Neuropsychopharmacology 29 11 2004 2108 2114
66. A. Giuffrida, L.H. Parsons, T.M. Kerr, F. Rodríguez de Fonseca, M. Navarro, and D. Piomelli Dopamine activation of endogenous cannabinoid signaling in dorsal striatum Nat. Neurosci. 2 4 1999 358 363
67. J.M. Griffith, M. Waldo, L.E. Adler, and R. Freedman Normalization of auditory sensory gating in schizophrenic patients after a brief period for sleep Psychiatry Res. 49 1993 29 39
68. J. Griffith, L.D. Hoffer, L.E. Adler, G.O. Zerbe, and R. Freedman Effects of sound intensity on a mid latency evoked response to repeated auditory stimuli in schizophrenic and normal subjects Psychophysiology 32 1995 460 466
69. J.M. Griffith, J.E. O'Neill, F. Petty, D. Garver, D. Young, and R. Freedman Nicotinic receptor desensitization and sensory gating deficits in schizophrenia Biol. Psychiatry 44 1998 98 106
70. T. Grunwald, N.N. Boutros, N. Pezer, O.J. von, G. Fernandez, C. Schaller, and C.E. Elger Neuronal substrates of sensory gating within the human brain Biol. Psychiatry 53 2003 511 519
71. Y. Goto, and A.A. Grace Dopamine modulation of hippocampal-prefrontal cortical interaction drives memory-guided behaviour Cereb. Cortex 18 2008 1407 1414
72. M. Hajos, W.E. Hoffmann, and B. Kocsis Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia Biol. Psychiatry 63 2008 1075 1083
73. M. Hambrecht, and H. Häfner Substance abuse and the onset of schizophrenia Biol. Psychiatry 40 1996 1155 1163
74. M. Hambrecht, and H. Häfner Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective Aust. New Zealand J. Psychiatry 34 2000 468 475
75. R.E. Hampson, F. Miller, G. Palchik, and S.A. Deadwyler Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: implications for endocannabinoid control of hippocampal neural plasticity Neuropharmacology 60 2011 944 952
76. P.J. Harrison Schizophrenia: a disorder of neurodevelopment? Curr. Opin. Neurobiol. 7 1997 285 289 Review
77. P.J. Harrison The neuropathology of schizophrenia. A critical review data their interpretation Brain 122 1999 593 624 Review
78. W.P. Hetrick, C.A. Sandman, W.E. Bunney Jr., Y. Jin, S.G. Potkin, and M.H. White Gender differences in the gating of the auditory evoked potential in normal subjects Biol. Psychiatry 39 1996 51 58
79. M.A. Huestis, D.A. Gorelick, S.J. Heishman, K.L. Preston, R.A. Nelson, E.T. Moolchan, and R.A. Frank Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716 Arch. Gen. Psychiatry 58 2001 322 328
80. X. Hong, R.C. Chan, X. Zhuang, T. Jiang, X. Wan, J. Wang, B. Xiao, H. Zhou, L. Jiang, and B. Weng Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia Schizophr. Res. 108 1-3 2009 151 157
81. A.C. Howlett, C.S. Breivogel, S.R. Childers, S.A. Deadwyler, R.E. Hampson, and L.J. Porrino Cannabinoid physiology and pharmacology: 30 years of progress Neuropharmacology 47 2004 345 358
82. O.D. Howes, and S. Kapur The dopamine hypothesis of schizophrenia: version III-the final common pathway Schizophr. Bull. 35 3 2009 549 562 10.1093/schbul/sbp006
83. M. Ishikawa, and K. Hashimoto α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia Curr. Pharm. 17 2011 121 129
84. F. Jessen, C. Kucharski, T. Fries, A. Papassotiropoulos, K. Hoenig, W. Maier, and R. Heun Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease Am. J. Psychiatry 158 2001 1319 1321
85. C.A. Jones, D.J. Watson, and K.C. Fone Animal models of schizophrenia Br. J. Pharmacol. 164 2011 1162 1194 10.1111/j.1476-5381.2011.01386.x
86. M.R. Johnson, and L.E. Adler Transient impairment in P50 auditory sensory gating induced by a cold-pressor test Biol. Psychiatry 33 1993 380 387
87. S. Kapur Looking for a "biological test" to diagnose "schizophrenia": are we chasing red herrings? World Psychiatry 10 1 2011 32
88. M.A. Kisley, A. Olincy, and R. Freedman The effect of state on sensory gating: comparison of waking, REM and non-REM sleep Clin. Neurophysiol. 112 2001 1154 1165
89. M.A. Kisley, S.D. Polk, R.G. Ross, P.M. Levisohn, and R. Freedman Early postnatal development of sensory gating Neuroreport 14 2003 693 697
90. M.A. Kisley, T.L. Noecker, and P.M. Guinther Comparison of sensory gating to mismatch negativity and self-reported perceptual phenomena in healthy adults Psychophysiology 41 2004 604 612
91. R.T. Knight, D. Scabini, and D.L. Woods Prefrontal cortex gating of auditory transmission in humans Brain Res. 504 1989 338 342
92. V. Knott, A. Millar, and D. Fisher Sensory gating and source analysis of the auditory P50 in low and high suppressors NeuroImage 44 2009 992 1000
93. V. Knott, A. Millar, D. Fisher, and P. Albert Effects of nicotine on the amplitude and gating of the auditory P50 and its influence by dopamine D2 receptor gene polymorphism Neuroscience 166 2010 145 156
94. M. Krause, W.E. Hoffmann, and M. Hajos Auditory sensory gating in hippocampus and reticular thalamic neurons in anesthetized rats Biol. Psychiatry 53 2003 244 253
95. M. Kurthen, P. Trautner, T. Rosburg, T. Grunwald, T. Dietl, K.U. Kuhn, C. Schaller, C.E. Elger, H. Urbach, K. Elisevich, and N.N. Boutros Towards a functional topography of sensory gating areas: invasive P50 recording and electrical stimulation mapping in epilepsy surgery candidates Psychiatry Res. 155 2007 121 133
96. V.M. Leavitt, S. Molholm, W. Ritter, M. Shpaner, and J.J. Foxe Auditory processing in schizophrenia during the middle latency period (10-50 ms): high-density electrical mapping and source analysis reveal subcortical antecedents to early cortical deficits J. Psychiatry Neurosci. 32 2007 339 353
97. F.M. Leweke, D. Piomelli, F. Pahlisch, D. Muhl, C. Gerth, C. Hoyer, J. Klosterkötter, J. Hellmich, and D. Koethe Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia Transl. Psychiatry 2 3 2012 e94
98. F.M. Leweke, A. Giuffrida, U. Wurster, H.M. Emrich, and D. Piomelli Elevated endogenous cannabinoids in schizophrenia Neuroreport 10 8 1999 1665 1669
99. G.A. Light, and D.L. Braff Sensory gating deficits in schizophrenia: can we parse the effects of medication, nicotine use, and changes in clinical status? Clin. Neurosci. Res. 3 2003 47 54
100. P.E. Mallet, and R.J. Beninger The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9- tetrahydrocannabinol or anandamide Psychopharmacology (Berl) 140 1998 11 19
101. C. Mann, R.J. Croft, K.E. Scholes, A. Dunne, B.V. O'Neill, S. Leung, D. Copolov, K.L. Phan, and P.J. Nathan Differential effects of acute serotonin and dopamine depletion on prepulse inhibition and p50 suppression measures of sensorimotor and sensory gating in humans Neuropsychopharmacology 33 2008 1653 1666
102. E.R. Marcotte, D.M. Pearson, and L.K. Srivastava Animal models of schizophrenia: a critical review J. Psychiatry Neurosci. 26 2001 395 410
103. R.S. Martin, R.L. Secchi, E. Sung, M. Lemaire, D.W. Bonhaus, L.R. Hedley, and D.A. Lowe Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat Psychopharmacology 165 2003 128 135
104. A. Martinez, T. Macheda, M.G. Morgese, L. Trabace, and A. Giuffrida The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats Neurosci. Res. 72 3 2012 236 242
105. P.J. Marshall, Y. Bar-Haim, and N.A. Fox The development of P50 suppression in the auditory event-related potential Int. J. Psychophysiol. 51 2004 135 141
106. R. Melamede Harm reduction-the cannabis paradox Harm Reduction J. 2 2005 17 10.1186/1477-7517-2-17
107. H.Y. Meltzer, L. Arvanitis, D. Bauer, and W. Rein Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective e disorder Am. J. Psychiatry 161 2004 975 984
108. C.L. Miller, P.C. Bickford, V. Luntz-Leybman, L.E. Adler, G.A. Gerhardt, and R. Freedman Phencyclidine and auditory sensory gating in the hippocampus of the rat Neuropharmacology 31 1992 1041 1048
109. C.L. Miller, and R. Freedman Medial septal neuron activity in relation to an auditory sensory gating paradigm Neuroscience 55 1993 373 380
110. C.L. Miller, and R. Freedman The activity of the hippocampal interneurons and pyramidal cells during the response of the hippocampus to repeated auditory stimuli Neuropharmacology 31 1995 1041 1048
111. T.H. Moore, S. Zammit, A. Lingford-Hughes, T.R. Barnes, P.B. Jones, M. Burke, and G. Lewis Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review Lancet 370 2007 319 328 Review
112. K.A. Moxon, G.A. Gerhardt, P.C. Bickford, K. Austin, G.M. Rose, D.J. Woodward, and L.E. Adler Multiple single units and population responses during inhibitory gating of hippocampal auditory response in freely-moving rats Brain Res. 17 825 1999 75 85
113. K.A. Moxon, G.A. Gerhardt, and L.E. Adler Dopaminergic modulation of the P50 auditory-evoked potential in a computer model of the CA3 region of the hippocampus: its relationship to sensory gating in schizophrenia Biol. Cybern. 88 2003 265 275
114. K.A. Moxon, G.A. Gerhardt, M. Gulinello, and L.E. Adler Inhibitory control of sensory gating in a computer model of the CA3 region of the hippocampus Biol. Cybern. 88 2003 247 264
115. M. Murakami, H. Kashiwadani, Y. Kirino, and K. Mori State-dependent sensory gating in olfactory cortex Neuron 46 2005 285 296
116. H.T. Nagamoto, L.E. Adler, M.C. Waldo, and R. Freedman Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval Biol. Psychiatry 25 1989 549 561
117. H.T. Nagamoto, L.E. Adler, R.A. Hea, J.M. Griffith, K.A. McRae, and R. Freedman Gating of auditory P50 in schizophrenics: unique effects of clozapine Biol. Psychiatry 40 1996 181 188
118. K.H. Nuechterlein, and M.E. Dawson Neurophysiological and Psychophysiological Approaches to Schizophrenia and Its Pathogenesis (Electronic Review) 2005 http://www.acnp.org/g4/GN401000119/CH117 (accessed 03.08.11.)
119. T.C. Neylan, D.J. Fletcher, M. Lenoci, K. McCallin, D.S. Weiss, F.B. Schoenfeld, C.R. Marmar, and G. Fein Sensory gating in chronic posttraumatic stress disorder: reduced auditory P50 suppression in combat veterans Biol. Psychiatry 46 1999 1656 1664
120. H. Ninomiya, E. Sato, T. Onitsuka, T. Hayashida, and N. Tashiro Auditory P50 obtained with a repetitive stimulus paradigm shows suppression to high-intensity tones Psychiatry Clin. Neurosci. 54 2000 493 497
121. G. Patrick, J.J. Straumanis, F.A. Struve, M.J. Fitz-Gerald, J. Leavitt, and J.E. Manno Reduced P50 auditory gating response in psychiatrically normal chronic marihuana users: a pilot study Biol. Psychiatry 45 1999 1307 1312
122. G. Patrick, and F.A. Struve Reduction of auditory P50 gating response in marihuana users: further supporting data Clin. Electroencephalogr. 31 2000 88 93
123. J.V. Patterson, W.P. Hetrick, N.N. Boutros, Y. Jin, C. Sandman, H. Stern, S. Potkin, and W.E. Bunney Jr. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis Psychiatry Res. 158 2008 226 247
124. T. Pattij, M.C. Janssen, I. Schepers, G. González-Cuevas, T.J. de Vries, and A.N. Schoffelmeer Effects of the cannabinoid CB1 receptor antagonist rimonabant on distinct measures of impulsive behavior in rats Psychopharmacology (Berl) 193 2007 85 96
125. M. Pistis, G. Porcu, M. Melis, M. Diana, and G.,L. Gessa Effects of cannabinoids on Prefrontal neuronal responses in ventral tegmental area stimulation Eur. J. Neurosci. 14 2001 96 102
126. D. Potter, A. Summerfelt, J. Gold, and R.W. Buchanan Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia Schizophr. Bull. 32 2006 692 700
127. L. Rasco, R.D. Skinner, and E. Garcia-Rill Effect of age on sensory gating of the sleep state-dependent P1/P50 midlatency auditory evoked potential Sleep Res. Online 3 2000 97 105
128. J. Rentzsch, A. Penzhorn, K. Kernbichler, D. Plockl, C.A. Gomez-Carrillo de, J. Gallinat, and M.C. Jockers-Scherubl Differential impact of heavy cannabis use on sensory gating in schizophrenic patients and otherwise healthy controls Exp. Neurol. 205 2007 241 249
129. J. Rentzsch, C.A. Gomez-Carrillo de, A. Neuhaus, M.C. Jockers-Scherubl, and J. Gallinat Comparison of midlatency auditory sensory gating at short and long interstimulus intervals Neuropsychobiology 58 2008 11 18
130. J. Rentzsch, M.C. Jockers-Scherubl, N.N. Boutros, and J. Gallinat Test-retest reliability of P50, N100 and P200 auditory sensory gating in healthy subjects Int. J. Psychophysiol. 67 2008 81 90
131. T. Rosburg, K.A. Andermahr, H. Nowak, and H. Saur Habituation of auditory evoked field component N100 in male patients with schizophrenia J. Psychiatry Research 34 2000 245 254
132. P. Roser, and I.S. Haussleiter Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies Curr. Pharm. Des. 2012, June 7 http://www.ncbi.nlm.nih.gov/pubmed/22716153 (accessed 25.09.12.)
133. P. Roser, I.S. Haussleiter, H.J. Chong, C. Maier, W. Kawohl, C. Norra, and G. Juckel Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia Psychopharmacology (Berl) 218 4 2011 611 620
134. A.,H. Sam, V. Salem, and M.,A. Ghatei Rimonabant: from Rio to Ban J. Obes. 2011 432607 2011 4 10.1155/2011/432607
135. E.M. Sánchez-Morla, J.L. Santos, A. Aparicio, M.A. García-Jiménez, C. Villanueva, V. Martínez-Vizcaíno, and C. Arango Antipsychotic effects on auditory sensory gating in schizophrenia patients Eur. Neuropsychopharmacol. 19 12 2009 905 909
136. M. Schneider, and M. Koch The cannabinoid agonist WIN 55,212-2 reduces sensorimotor gating and recognition memory in rats Behav. Pharmacol. 13 2002 29 37
137. M. Schneider, and M. Koch Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats Neuropsychopharmacology 28 2003 1760 1769
138. K.E. Scholas-Balog, and M.T. Martin-Iverson Cannabis use and sensory motor gating in patients with schizophrenia and healthy control Hum. Psychopharmacol. 12 2011 599 614
139. J. Seifert, S. Ossege, H.M. Emrich, U. Schneider, and M. Stuhrmann No association of CNR1 gene variations with susceptibility to schizophrenia Neurosci. Lett. 426 1 2007 29 33
140. A. Sellier, T. Advani, T. Cassano, J.G. Hensler, and A. Giuffrida Inhibition of fatty-acidamide hydrolase and CB1 antagonism differentially affect behavioural responses in normal and PCP-treated rats Int. J. Neuropharmacol. 13 2010 373 386
141. R.A. Sewell, M. Ranganathan, and D.C. D'Souza Cannabinoids and psychosis Int. Rev. Psychiatry 21 2009 152 162 Review
142. L.J. Sim-Selley, L.K. Brunk, and D.E. Selley Inhibitory effects of SR141716A on G-protein activation in rat brain Eur. J. Pharmacol. 414 2001 135 143
143. J.K. Simosky, K.E. Stevens, L.E. Adler, and R. Freedman Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism Psychopharmacology (Berl) 165 2003 386 396
144. J.K. Simosky, R. Freedman, and K.E. Stevens Olanzapine improves deficient sensory inhibition in DBA/2 mice Brain Res. 1233 2008 129 136
145. C. Siegel, M. Waldo, G. Mizner, L.E. Adler, and R. Freedman Deficits in sensory gating in schizophrenic patients and their relatives. Evidence obtained with auditory evoked responses Arch. Gen. Psychiatry 41 1984 607 612
146. N. Solowij, and P.T. Michie Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J. Psychiatry Neurosci. 32 2007 30 52 Review
147. M.S. Spano, P. Fadda, R. Frau, L. Fattore, and W. Fratta Cannabinoid self- administration attenuates PCP-induced schizophrenia-like symptoms in adult rats Eur. Neuropsychopharmacol. 20 2010 25 36
148. K.E. Stevens, L.L. Fuller, and G.M. Rose Dopaminergic and noradrenergic modulation of amphetamine-induced changes in auditory gating Brain Res. 555 1991 91 98
149. K.E. Stevens, J. Meltzer, and G.M. Rose Disruption of sensory gating by the alpha 2 selective noradrenergic antagonist yohimbine Biol. Psychiatry 33 1993 130 132
150. K.E. Stevens, and K.D. Wear Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models Pharmacol. Biochem. Behav. 57 1997 869 874
151. K.E. Stevens, A.E. Bullock, and A.C. Collins Chronic corticosterone treatment alters sensory gating in C3H mice Pharmacol. Biochem. Behav. 69 2001 359 366
152. A. Straiker, and K. Mackie Cannabinoids, electrophysiology, and retrograde messengers: challenges for the next 5 years AAPS J. 8 2006 272 276
153. S. Sundram, D. Copolov, and B. Dean Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens Naunyn Schmiedebergs Arch. Pharmacol. 371 2005 428 433
154. C.A. Tamminga The promise of new drugs for schizophrenia treatment Can. J. Psychiatry 42 1997 265 273 Review
155. C.A. Tamminga The science of antipsychotics: mechanistic insight CNS Spectr. 11 Suppl. 2 2003 5 9
156. R.J. Thoma, F.M. Hanlon, S.N. Moses, D. Ricker, M. Huang, C. Edgar, J. Irwin, F. Torres, M.P. Weisend, L.E. Adler, G.A. Miller, and J.M. Canive M50 sensory gating predicts negative symptoms in schizophrenia Schizophr. Res. 73 2005 311 318
157. R.J. Thoma, F.M. Hanlon, M. Huang, G.A. Miller, S.N. Moses, M.P. Weisend, A. Jones, K.M. Paulson, J. Irwin, and J.M. Canive Impaired secondary somatosensory gating in patients with schizophrenia Psychiatry Res. 151 2007 189 199
158. J.R. Tregellas, D.B. Davalos, D.C. Rojas, M.C. Waldo, L. Gibson, K. Wylie, Y.P. Du, and R. Freedman Increased hemodynamic response in the hippocampus, thalamus and prefrontal cortex during abnormal sensory gating in schizophrenia Schizophr. Res. 92 2007 262 272
159. S.J. Tsai, Y.C. Wang, and C.J. Hong Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia Psychiatr. Genet. 10 3 2000 149 151
160. E.T. Tzavara, R.J. Davis, K.W. Perry, X. Li, C. Salhoff, F.P. Bymaster, J.M. Witkin, and G.G. Nomikos The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions Br. J. Pharmacol. 138 2003 544 553
161. H. Ujike, and Y. Morita New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia J. Pharm. Sci. 96 2004 376 381 Review
162. E.L.J.M. van Luijtelaar, C.A. Miller, A.M. Coenen, W.H. Drinkenburg, and B.A. Ellenbroek Differential effects of non-REM and REM sleep on sensory gating in rats Acta Neurobiol. Exp. (Wars.) 58 1998 263 270
163. E.L.J.M. van Luijtelaar, P.F. Fabene, B.N. de, C. Jongema, B.A. Ellenbroek, and J.G. Veening Neural correlates of sensory gating in the rat: decreased Fos induction in the lateral septum Brain Res. Bull. 54 2001 145 151
164. D. Vigano, C. Guidali, S. Petrosin, N. Realini, T. Rubino, V. DiMarzo, and D. Parolaro Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia Int. J. Neuropsychopharmacol. 12 2009 599 614
165. M.C. Waldo, L.E. Adler, and R. Freedman Defects in auditory sensory gating and their apparent compensation in relatives of schizophrenics Schizophr. Res. 1 1988 19 24
166. M.C. Waldo, E. Cawthra, L.E. Adler, S. Dubester, M. Staunton, H. Nagamoto, N. Baker, A. Madison, J. Simon, and A. Scherzinger Auditory sensory gating, hippocampal volume, and catecholamine metabolism in schizophrenics and their siblings Schizophr. Res. 12 1994 93 106
167. M.C. Waldo, L.E. Adler, S. Leonard, A. Olincy, R.G. Ross, J.G. Harris, and R. Freedman Familial transmission of risk factors in the first-degree relatives of schizophrenic people Biol. Psychiatry 47 3 2000 231 239 Review
168. J.L. Wiley, S.H. Kendler, J.J. Burston, D.R. Howard, D.E. Selley, and L.J. Sim-Selley Antipsychotic-induced alterations in CB(1) receptor-mediated G-protein signaling and in vivo pharmacology in rats Neuropharm. 55 2008 1183 1190
169. E.J. Williams, F.S. Walsh, and P. Doherty The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response J. Cell. Biol. 160 2003 481 486
170. R.I. Wilson, and R.A. Nicoll Endocannabinoid signaling in the brain Science 296 2002 678 682
171. P.B. Yang, A.C. Swann, and N. Dafny Sensory-evoked potentials recordings from the ventral tegmental area, nucleus accumbens, prefrontal cortex, and caudate nucleus and locomotor activity are modulated in dose-response characteristics by methylphenidate Brain Res. 1073-1074 2006 164 174
172. C.M. Yee, and P.M. White P50 sensitivity to physical and psychological influences Psychophysiology 43 2001 320 328
173. M. Zachariou, D. Dissanayake, M. Owen, R. Mason, and S. Coombes The role of cannabinoids in the neurobiology of sensory gating: a firing rate model study Neurocomputing 70 2007 1902 1906
174. M. Zachariou, W.D.N. Dissanayake, M.R. Owen, R. Mason, and S. Coombes Sensory gating and its modulation by cannabinoids: electrophysiological, computational and mathematical analysis Cogn. Neurodynamics 2 2008 159 170
175. K. Zavitsanou, T. Garrick, and X.F. Huang Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia Prog. Neuropsychopharmacol. Biol. Psychiatry 28 2004 355 360
176. D. Zhou, Y. Ma, N. Liu, L. Chen, M. He, and Y. Miao Influence of physical parameters of sound on the sensory gating effects of N40 in rats Neurosci. Lett. 432 2008 100 104
177. G. Zouridakis, N.N. Boutros, and B.H. Jansen A fuzzy clustering approach to study the auditory P50 component in schizophrenia Psychiatry Res. 69 1997 169 181